APOE and Alzheimer disease: To examine whether these iPSC-neurons can serve as a model to develop AD therapies, Wang et al. design a proof of concept experiment by treating APOE 44 human iPSC-neurons with PH002, a small molecule structure corrector known to render ApoE4 molecule an ApoE3-like conformation (Figure 2A).